We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609.
- Authors
McLouth, Laurie E.; Zheng, Yue; Smith, Stephanie; Hodi, F. Stephen; Rao, Uma N.; Cohen, Gary I.; Amatruda, Thomas T.; Dakhil, Shaker R.; Curti, Brendan D.; Nakhoul, Ibrahim; Chandana, Sreenivasa R.; Bane, Charles L.; Marinier, David E.; Lee, Sandra J.; Sondak, Vernon K.; Kirkwood, John M.; Tarhini, Ahmad A.; Wagner, Lynne I.
- Abstract
Purpose: Trial E1609 demonstrated superior overall survival with ipilimumab 3 mg/kg (ipi3) compared to high-dose interferon (HDI) for patients with resected high-risk melanoma. To inform treatment tolerability, we compared health-related quality of life (HRQoL), gastrointestinal (GI), and treatment-specific physical and cognitive/emotional symptoms. We also compared treatment-specific concerns between all arms. Methods: We assessed HRQoL using the Functional Assessment of Cancer Therapy-General, physical and cognitive/emotional concerns using the FACT-Biologic Response Modifier subscale, and GI symptoms with the Functional Assessment of Chronic Illness Therapy-Diarrhea subscale pre-treatment and every 3 months. The primary outcome was the difference in HRQoL at 3 months between ipi3/ipi10 vs. HDI. Results: 549 patients (n = 158 ipi3; n = 191 ipi10; n = 200 HDI) were analyzed. 3-month completion was 58.7%. Compared to HDI, ipilimumab patients reported better HRQoL (ipi3 = 87.5 ± 14.6 vs. HDI = 74.7 ± 15.4, p <.001; ipi10 = 84.9 ± 16.5 vs. HDI, p <.001) and fewer physical (ipi3 = 22.3 ± 4.6 vs. HDI = 17.1 ± 5.4, p <.001; ipi10 = 21.8 ± 5.0 vs. HDI p <.001) and cognitive/emotional (ipi3 = 18.6 ± 4.4 vs. HDI = 15.0 ± 5.3, p <.001; ipi10 = 17.7 ± 4.8 vs. HDI p <.001) concerns, but worse GI symptoms (ipi3 = 40.8 ± 5.0 vs. HDI = 42.2 ± 2.9, p =.011; ipi10 = 39.5 ± 7.0 vs. HDI, p <.001). Fewer ipilimumab patients reported worsening treatment-specific concerns (e.g., 52% of ipi3 and 58% of ipi10 reported worsening fatigue vs. 82% HDI, p's <.001). Conclusion: PROs demonstrated less toxicity of ipi3 compared to HDI and ipi10. Priorities for symptom management among patients receiving ipilimumab include GI toxicities, fatigue, weakness, appetite loss, arthralgia, and depression. Trial Registration: NCT01274338, January 11, 2011 (first posted date) https://clinicaltrials.gov/ct2/show/NCT01274338?term=NCT01274338&draw=2&rank=1.
- Subjects
IPILIMUMAB; MELANOMA; QUALITY of life; INTERFERONS; ADJUVANT treatment of cancer
- Publication
Quality of Life Research, 2023, Vol 32, Issue 1, p183
- ISSN
0962-9343
- Publication type
Article
- DOI
10.1007/s11136-022-03226-8